This third Citizen Petition it seems TEVA addressed the 5 criteria that were used to approve enoxaparin. The FDA basically said each product is unique and the Agency has the capability to determine whether a product is approvable or not based on the science provided by the applicant.
"At this time, the Agency does not believe that the issues cited by you regarding Copaxone merit a referral to an advisory committee. The Agency believes that it has sufficient expertise to evaluate whether any purported generic glatiramer acetate could satisfy the sameness requirement with respect to Copaxone."
Market Data 
Markets 
AI
